Physician Views: Can Johnson & Johnson's Tremfya ride in Stelara's slipstream?

Last week the FDA approved Johnson & Johnson's Tremfya (guselkumab) for the treatment of moderate-to-severe psoriasis. The antibody, which selectively blocks IL-23, should complement Johnson & Johnson's existing blockbuster Stelara and allow the company to compete more effectively with newer IL-17 agents, such as Novartis' Cosentyx and Eli Lilly's Taltz. To gauge prescriber opinion towards Tremfya we are snap-polling US dermatologists with the following questions…

Johnson & Johnson's Tremfya (guselkumab), the first biologic that selectively blocks IL-23, has been approved by the FDA for the treatment of moderate-to-severe plaque psoriasis. How would you describe your awareness/knowledge of this product?

Not aware

Slightly aware

Moderately aware

Very aware

Extremely aware

Johnson & Johnson note that seven out of 10 patients receiving Tremfya achieved at least 90% improvement in skin clearance at week 16, while nearly three quarters of patients demonstrated at least 90% clearer skin at week 48. In head-to-head studies, Tremfya demonstrated superior results versus Humira at weeks 16, 24 and 48. Taking into account these data and existing psoriasis treatments, how compelling an addition to the treatment paradigm is Tremfya?

Not compelling

Slightly compelling

Moderately compelling

Very compelling

Extremely compelling

Tremfya is administered as a 100mg subcutaneous injection every eight weeks, following two starter doses at weeks 0 and 4. Will this dosing schedule provide meaningful advantage over other biologic therapies?

No

Slight advantage

Moderate advantage

Significant advantage

Very significant advantage

Compared to the mechanism of action of Stelara (ustekinumab), which targets both IL-12 and IL-23, Tremfya more selectively targets IL-23. Do you feel your experience with Stelara will positively influence you adoption of Tremfya or will you treat this drug as a completely novel product?

Completely novel product

Slight positive influence

Moderately positive influence

Significant positive influence

Very significant positive influence

What product would you initially expect to use Tremfya most frequently in favour of?

Cosentyx

Enbrel

Humira

Otezla

Remicade

Siliq

Stelara

Taltz

Results and related analysis will shortly be published for FirstWord Pharma PLUS subscribers to read, with the opportunity for non-FirstWord Pharma PLUS subscribers to purchase these findings. To be notified when poll results and analysis become available, please click here.

As always, FirstWord would very much like to receive your feedback and suggestions. Note: FirstWord Polls are powered by Medefield MedePolls, a fast-turnaround service to conduct instant polls of up to five questions with guaranteed samples that include physicians from dozens of specialties and over 100 markets. To conduct this poll with a different audience, or an entirely different poll, contact us at info@firstwordpharma.com

To read more Physician Views articles, click here.